e-learning
resources
Vienna 2003
Sunday 28.09.2003
Work-related COPD - Organic dusts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What constitutes a rapid fall in serial FEV1?
P. L. Enright, O. C. Elci, K. Kreiss, D. Deubner, G. Wagner (Morgantown, Elmore, United States Of America)
Source:
Annual Congress 2003 - Work-related COPD - Organic dusts
Session:
Work-related COPD - Organic dusts
Session type:
Thematic Poster Session
Number:
801
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. L. Enright, O. C. Elci, K. Kreiss, D. Deubner, G. Wagner (Morgantown, Elmore, United States Of America). What constitutes a rapid fall in serial FEV1?. Eur Respir J 2003; 22: Suppl. 45, 801
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Re-assessing the importance of FEV
1
decline
Source: Eur Respir Monogr 2015; 69: 134-142
Year: 2015
How often FEV
1
underestimates bronchodilator response?
Source: Eur Respir J 2003; 22: Suppl. 45, 100s
Year: 2003
1 year RV/TLC change as a predictor of long term decline of FEV1
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
What are the merits of FEV1?
Source: International Congress 2014 – AirPROM: can imaging and modelling take us beyond FEV1?
Year: 2014
Do we need slow or forced expiration before the FIV1 measurement?
Source: Eur Respir J 2005; 26: Suppl. 49, 120s
Year: 2005
Dose omission to shorten methacholine challenge testing: clinical consequences and safety of the use of a "10% fall in FEV1" threshold
Source: International Congress 2018 – New methods and concepts in tests of lung and respiratory muscle function
Year: 2018
Prediction of all cause mortality in a population sample is improved by using FEV
1
quotient
Source: Annual Congress 2005 - Assessing the relevance of obstructive airway diseases
Year: 2005
When is FEV
1
loss excessive? – an investigation of the relationship between year-to-year and long-term spirometry changes
Source: Annual Congress 2004 - Longitudinal studies and determinants of lung function and COPD
Year: 2004
Serial FEV1 measurements: an improved diagnostic tool for occupational asthma?
Source: International Congress 2017 – Asthma: clinical and epidemiologic characterisation
Year: 2017
Has the determination of the rate of decline of FEV1 added value in addition to the determination of FEV1/FVC and FEV1
Source: International Congress 2016 – Man versus machine: waves, frequency, and more in lung function
Year: 2016
Comparison of variations of FEV
1
and forced oscillation technique during methacholine challenge
Source: Eur Respir J 2004; 24: Suppl. 48, 339s
Year: 2004
FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Exploring the clinical utility of measuring reversibility in mid expiratory flow and its relationship with FEV1 reversibility in patients with asthma.
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
A one-week period of home spirometry provides a reliable reflection of PEF and FEV1 variation in children with and without asthma
Source: Annual Congress 2007 - Assessing asthma severity and control in children
Year: 2007
LVRS does not accelerate rate of decline in FEV
1
Source: Eur Respir J 2003; 22: Suppl. 45, 369s
Year: 2003
Early life origins of adult lung function
Source: Annual Congress 2006 - Highlights of epidemiology of COPD and lung function
Year: 2006
Can the prediction point for FEV1 / FVC be determined in patients with insufficient expiratory maneuver to determine airflow obstruction?
Source: Virtual Congress 2020 – Advances in lung function testing
Year: 2020
FEV
1
/FEV
3
ratio: a potential alternative to full spirometry for patients unable to sustain forced expiration?
Source: Annual Congress 2007 - Lung function and therapy in obstructive lung diseases
Year: 2007
Annual decline in forced expiratory volume in 1 sec (FEV1) in patients with COPD before and after introduction of tiotropium
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
The relationship between peak expiratory flow rate (PEFR) and forced expiratroy volume in the first second (FEV1) at low levels of FEV1. Implications for the assessment of COPD (chronic obstructive pulmonary disease) in primary care
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept